HK Stock Market Move | HWORLD-S (01179) has risen over 4%. The second-quarter profit has nearly doubled compared to the previous quarter, and the company has actively raised its full-year performance guidance.
Huazhu Group-S (01179) is currently up over 4%. As of the time of publication, it has risen 4.65% to HKD 38.28, with a turnover of HKD 143 million.
HWORLD-S (01179) is currently up over 4%. As of the time of this report, it has risen by 4.65%, trading at HKD 38.28, with a transaction volume of HKD 143 million.
In terms of news, Huazhu Group reported a revenue of 13.1 billion yuan in the first half of the year, a year-on-year increase of 11%; the net profit attributable to the company was 2.4 billion yuan, remaining flat year-on-year. In the second quarter alone, the company achieved a revenue of 7.1 billion yuan, a quarter-on-quarter increase of about 18.78%; the net profit attributable to the company was 1.6 billion yuan, nearly doubling from the previous quarter. Notably, Huazhu Group has proactively raised its performance guidance for the full year of 2026, expecting revenue growth to range between 4% and 8%, up from the previous guidance of 2% to 6%.
Guosen pointed out that since the second half of last year, the improvement in the domestic hotel cycle has been gradually validated, demonstrating the company's strong performance elasticity; however, since May, travel chains have been weakened due to external oil price and weather impacts, disrupting investor sentiment. Nevertheless, the company leverages its operational management efficiency to realize gains based on a healthy ecosystem, capitalizing on scalability advantages, improving light asset profit margins, and actively enhancing shareholder returns, thereby highlighting its value as a leading stock and maintaining an "outperform" rating.
Related Articles

Humanwell Healthcare (600079.SH): RFUS-188 injection has entered Phase II clinical trials.

Humanwell Healthcare (600079.SH): Midazolam Injection has received marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

HK Stock Market Move | Some inner property stocks rose in the afternoon as multiple departments in Shanghai jointly issued the "Eight Regulations" to optimize real estate control policies.
Humanwell Healthcare (600079.SH): RFUS-188 injection has entered Phase II clinical trials.

Humanwell Healthcare (600079.SH): Midazolam Injection has received marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

HK Stock Market Move | Some inner property stocks rose in the afternoon as multiple departments in Shanghai jointly issued the "Eight Regulations" to optimize real estate control policies.

RECOMMEND





